Ireland
--:--IST
Starting soon Not applicable

Cold Snare Versus Cold Forceps Polypectomy for Small Lesions

NCT06970808 · tracked via the Priya Life Science Italy tracker
Sponsor
Azienda USL Modena
Phase
Not applicable
Started
2025-12
Last updated
2025-05-14

Condition(s) studied

Colorectal AdenomaColorectal Lesions

Investigational drug(s) / intervention(s)

Sampling from the resection margins

Sampling from the resection margins: After polypectomy, the base will be irrigated and assessed by the endoscopist, who may also use virtual or vital chromoendoscopy, if needed. Any residual adenomatous tissue will be removed using the same technique. To confirm the completeness of each polypectomy, two biopsies will be taken from the resection margins for polyps ≤ 5 mm, and three biopsies for polyps 6-9 mm, using standard biopsy forces.

Study summary

The goal of this clinical trial is to compare the efficacy and the safety of a new device for cold forceps polypectomy (CFP)- a special jumbo forceps- to cold snare polypectomy (CSP) for small colorectal lesions, without adding peri- or post-procedural risks to the patient.

The main questions it aims to answer are:

* Does the cold forceps guarantee a complete endoscopic resection rate?
* How many adverse events could the jumbo forceps reduce in comparison to CSP?
* Does the lesion retrieval rate increase?
* Does the polypectomy duration decrease? Participants will be randomized to one or to the other group when a polypoid or non-polypoid lesion is identified. If multiple polyps are found in the same patient, they will be removed using the same polypectomy technique.

If polypectomy cannot be performed using the indicated technique, a crossover will be done according to the best practice of care principles.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patients aged ≥ 18 years; * Ability to provide informed consent; * Presence of at least one colorectal polypoid/non-polypoid lesion \< 10 mm Exclusion Criteria: * Primary or secondary coagulopathy; * Improper interruption of dual antiplatelet therapy and/or antiplatelet therapy with P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor) and/or anticoagulant therapy; * Chronic inflammatory bowel diseases; * Inpatients undergoing colonoscopy; * Colonoscopy as part of regional colorectal cancer screening; * Pregnancy or breastfeeding

Primary outcome measure(s)

  • Incomplete resection rate — Immediately after the procedure and immediately after the histological evaluation of the biopsy samples
    Compare the rate of incomplete endoscopic resection (IER) of CFP and CSP, defined as the presence of residual adenomatous tissue in the biopsy samples of the margins or after the visual assessment of the resection base.

Trial sites (1)

FacilityCityRegionStatus
AUSL Modena Carpi Modena
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06970808 on ClinicalTrials.gov ↗ ← All trials in Italy